CION Ameerpet
After an organ or stem-cell transplant, the medicines that protect the graft can loosen the immune system's control over certain cells. This guide explains PTLD, the role of EBV, the warning signs and how CION's haematology team diagnoses and treats it.
Post-transplant lymphoproliferative disorder (PTLD) is a group of abnormal lymphoid growths that can appear after a solid-organ or stem-cell transplant. It sits on a spectrum: at one end, early, reactive lesions that may settle when anti-rejection medicines are reduced; at the other, an aggressive lymphoma that needs full treatment. Most cases arise from B cells, and many are driven by the Epstein-Barr virus (EBV).
The link is straightforward. To stop the body rejecting a transplant, doctors deliberately dampen the immune system. That same dampening also weakens the immune surveillance that normally keeps virus-infected and abnormal cells in check — which is the essence of immunosuppression lymphoma risk. It is important to keep this in perspective: PTLD is an uncommon complication, and most transplant recipients never develop it. But because early recognition changes outcomes, being informed is worthwhile.
This page is written for transplant recipients, their families, and anyone anxious about their risk. For the bigger picture of lymphoma care, see our Lymphoma hub, and for how treatment is planned, our Lymphoma Treatment in Hyderabad page.
PTLD is one of the most serious complications of transplantation, yet it remains uncommon overall. Published transplant series report that its frequency depends heavily on the organ transplanted, the intensity of immunosuppression and Epstein-Barr virus status — being EBV-negative at the time of transplant is a recognised risk factor. Because many cases are B-cell and EBV-driven, transplant teams may monitor EBV levels in higher-risk patients. (Source: NCCN and ESMO lymphoma guidelines; published transplant registry data. Figures vary by individual and transplant type.)
No single factor decides risk — it is a combination. Understanding your own profile helps you and your transplant team stay alert without becoming alarmed.
The higher the total amount and the longer the duration of anti-rejection therapy, the greater the risk. This is why transplant teams aim for the lowest effective dose that still protects the graft, and why the type of transplant matters.
Being EBV-negative before transplant — and then encountering the virus afterwards — is a recognised risk factor, particularly in younger recipients. EBV-driven B cells can grow unchecked when immune control is reduced. See our EBV & lymphoma page.
The same principle links other causes of long-term immune suppression to lymphoma, including HIV and some autoimmune diseases treated with immune-suppressing therapy.
EBV-positive PTLD often appears earlier after transplant, while EBV-negative disease tends to appear later and can behave more like ordinary aggressive lymphoma. This timing helps guide monitoring.
Risk factors combine differently in every person. This is general guidance, aligned with NCCN and ESMO principles, not a personal risk estimate.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have new symptoms, a fresh PTLD diagnosis, or simply want to understand your personal risk, CION's haematology team can review your reports and put things in context — working alongside your transplant centre.
Because transplant recipients are already in close follow-up, PTLD is often picked up early. Any new or unexplained symptom deserves a prompt review with your transplant team — but the following are worth knowing:
Most of these symptoms have ordinary causes and are not PTLD. But if they are new, persistent or worsening, contact your transplant centre — and importantly, do not stop or change your anti-rejection medicines yourself. Speak to a CION haematologist if you would like your reports reviewed.
PTLD spans early, polymorphic and frankly malignant forms, and each is managed differently — so an accurate, tissue-based diagnosis comes first. CION delivers the biopsy coordination, molecular marker testing and staging directly.
A biopsy of an affected node or organ is the cornerstone. A pathologist examines the tissue, tests for B-cell markers such as CD20, assesses cell-of-origin, and checks for EBV. This determines exactly where on the PTLD spectrum a case sits.
A PET-CT scan maps where the disease is active, and a bone-marrow examination is added where indicated. This mirrors the standard lymphoma work-up described on our Lymphoma Treatment in Hyderabad page.
In higher-risk recipients, transplant teams may track EBV levels in the blood, since a rising level can be an early warning. This is decided jointly with your transplant centre. Every CION case is reviewed by a multidisciplinary tumour board, in coordination with your transplant physicians, before a plan is set.
The very first treatment step in many PTLD cases is not chemotherapy at all — it is carefully reducing the immunosuppression, done in close coordination with the transplant team. Early, reactive lesions can regress with this alone. Per NCCN and ESMO guidance, this transplant-aware, stepwise approach — reduce immune suppression first, then escalate only if needed — is what distinguishes PTLD management from the treatment of ordinary lymphoma. (Source: NCCN and ESMO lymphoma guidelines.)
Every PTLD plan balances two goals: controlling the lymphoma and protecting the transplanted organ. The right approach depends on the subtype, stage, EBV status and how the graft is functioning, and it is always made together with your transplant team. The main building blocks are:
Where it is safe to do so, the first move is to reduce the anti-rejection medicines — this alone can allow early lesions to regress by restoring some immune control. This step is always coordinated with the transplant team, since it carries a risk to the graft and must be balanced carefully.
If more treatment is needed, an anti-CD20 monoclonal antibody is often used for CD20-positive B-cell disease, sometimes alone and sometimes with chemotherapy (described here by drug class only). We do not name specific regimens on this page — your specialist will match the right protocol to your subtype and stage. See our Treatment page for how regimens are selected. CION delivers immunotherapy and systemic chemotherapy directly.
For disease confined to one area, precision radiation therapy (IMRT/IGRT) may be used, delivered directly by CION. Cellular therapies and any transplant-related procedures, where relevant, are coordinated through accredited partner facilities rather than delivered in-house.
Alongside treatment, CION manages infection prevention, supportive care and long-term survivorship follow-up — recognising that PTLD patients need coordinated care between the oncology and transplant teams for years afterward.
Outcomes in PTLD vary widely because the disorder itself is so varied — from lesions that settle when immunosuppression is reduced to aggressive lymphomas needing full treatment. The good news is that outcomes for B-cell PTLD have improved markedly since antibody-based approaches became standard, and many patients achieve durable control.
For context, published lymphoma series report broad survival ranges by subtype — for example, Hodgkin lymphoma around 80–90% and diffuse large B-cell lymphoma around 60–70% long-term survival — though PTLD is its own category and figures differ by individual, transplant type and how early it is found. These numbers are attributed to published series (as referenced in NCCN and ESMO guidance) and are general figures; your own outlook depends on many personal factors your specialist will explain.
If you would like your personal situation put in context, CION offers a free written second opinion. You deserve a plan built around healing, not billing. Request your free second opinion or call 18002028726. You can also read about the family-risk side of lymphoma, hepatitis C and other prevention questions — and see our Best Lymphoma Doctors in Hyderabad and Best Lymphoma Hospital in Hyderabad pages.
Get a free written second opinion from CION's haematology tumour board — especially valuable to confirm the subtype and to plan treatment that protects your transplanted organ.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.PTLD is a group of abnormal lymphoid growths that can develop after an organ or stem-cell transplant, when the anti-rejection medicines that suppress the immune system also weaken its ability to control certain infected cells. It ranges from early, reactive lesions that may settle when immunosuppression is reduced, all the way to an aggressive lymphoma that needs full treatment. Most cases are of B-cell origin and many are linked to the Epstein-Barr virus (EBV). Because the spectrum is so wide, an accurate biopsy and classification are essential before any treatment decision. NCCN and ESMO both recognise PTLD as a distinct category that needs transplant-aware management.
A healthy immune system constantly finds and destroys cells that are infected by viruses such as EBV or that have begun to behave abnormally. The drugs that stop the body rejecting a transplanted organ deliberately dampen this surveillance — and that same dampening can let virus-driven B cells multiply unchecked, which is the core of immunosuppression lymphoma risk. The higher the total amount and duration of immunosuppression, the greater the risk. This is why transplant teams use the lowest effective dose and monitor high-risk patients. The same principle explains why other causes of long-term immune suppression, such as HIV, also raise lymphoma risk.
EBV is a very common virus that most adults carry harmlessly for life, kept in check by the immune system. After a transplant, when immune control is reduced, EBV-infected B cells can grow unchecked and drive many — though not all — cases of PTLD. EBV-positive PTLD tends to appear earlier after transplant, while EBV-negative disease often appears later and can behave more like ordinary aggressive lymphoma. Because of this link, transplant teams may monitor EBV levels in the blood in high-risk patients. You can read more about the wider connection on our EBV & lymphoma page.
PTLD can be subtle, so any new or unexplained symptom after a transplant deserves a prompt review with your transplant team. Common signs include swollen lymph nodes that do not settle, unexplained fever, drenching night sweats, unintended weight loss, tiredness, or symptoms related to the transplanted organ not working as well. Sometimes the disease shows up in the gut, chest or brain rather than the nodes. Because transplant recipients are already under close follow-up, these symptoms are often picked up early. If you notice them, contact your transplant centre — do not stop or change your anti-rejection medicines yourself. A CION specialist can also review your reports.
Diagnosis begins with a biopsy of an affected node or organ, examined by a pathologist. The tissue is tested for markers such as CD20 (a B-cell marker), assessed for cell-of-origin, and checked for EBV. Staging usually involves a PET-CT scan and a bone-marrow examination where needed. This is exactly the same careful, tissue-based approach used for other lymphomas — for the general work-up, see our Lymphoma Treatment in Hyderabad page. Accurate classification matters because PTLD spans early, polymorphic and frankly malignant forms, and each is managed differently. At CION, biopsy, molecular marker testing and staging are delivered directly and reviewed by a tumour board.
The first and often unique step in PTLD is, where safe, reducing the immunosuppression in close coordination with the transplant team — early lesions can regress with this alone. If more is needed, treatment may add an anti-CD20 monoclonal antibody, chemotherapy (by drug class), radiation, or a combination, chosen by the subtype and stage. We do not name specific drug regimens here — your specialist will match the right protocol to your case; see our Treatment page for how regimens are selected. Many patients achieve good control, and outcomes for B-cell PTLD have improved markedly with antibody-based approaches. Every plan is a careful balance between treating the lymphoma and protecting the transplanted organ.
No. The great majority of transplant recipients never develop PTLD. It is an uncommon complication, and the absolute risk depends on the type of transplant, the intensity and duration of immunosuppression, EBV status and age. Being aware of the risk is useful — not because it is likely, but because early recognition leads to better outcomes. The best protection is staying in regular follow-up, taking anti-rejection medicines exactly as prescribed, and reporting new symptoms promptly. If you are anxious about your personal risk or want a report reviewed, a free consultation with a CION haematologist can put the numbers in context. Figures vary by individual.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.